Aurobindo Pharma

1,082.45
+24.45
(2.31%)
Market Cap
62,868.87 Cr
EPS
54.16
PE Ratio
17.41
Dividend Yield
0.43 %
Industry
Healthcare
52 Week High
1,592.00
52 Week Low
1,010.00
PB Ratio
2.00
Debt to Equity
0.21
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from25 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+76.00 %
+76.00 %
Hold
Hold+8.00 %
+8.00 %
Sell
Sell+16.00 %
+16.00 %

Company News

View All News
Caret
positive
Aurobindo Pharma: FDA Approves Generic Xarelto 2.5mg, Eyeing $447M Market1 day ago
Aurobindo Pharma received USFDA final approval for generic Rivaroxaban 2.5mg tablets. Launch planned for Q1 FY2025-26. US market size for this strength is $447M. Tentative approvals secured for 10mg, 15mg, and 20mg strengths. Total Rivaroxaban market in US estimated at $8.5B.
neutral
Aurobindo Pharma's Raleigh Plant Receives FDA Observations3 days ago
Aurobindo Pharma's facility in Raleigh has received 11 procedural observations from the U.S. Food and Drug Administration (FDA) following an inspection. The company states that these observations are not expected to have a significant impact on the plant's operations.
positive
Aurobindo Pharma's Unit Completes Phase 1 Study for Denosumab Biosimilar4 days ago
Curateq Biologics, a unit of Aurobindo Pharma, has successfully completed a Phase 1 pharmacokinetics study of BP16, a proposed biosimilar to Prolia® and Xgeva® (denosumab). This marks a significant step in the development of a potential alternative to these established osteoporosis and bone loss treatments.
View more
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
#10 62,868.87
#2 17.41
#2 29,559.20
#3 17.55
#5 3,169
#9 -10.04
41.61

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
17.55 %
Net Income Growth
64.39 %
Cash Flow Change
2.00 %
ROE
47.91 %
ROCE
46.65 %
EBITDA Margin (Avg.)
35.82 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
3,151
3,272
3,324
3,450
3,710
3,728
3,742
3,871
3,625
3,645
4,366
4,302
4,033
4,226
4,694
5,242
5,234
5,377
5,539
5,830
6,108
5,951
6,432
9,300
6,071
5,802
5,987
6,089
5,844
6,218
5,731
6,481
6,514
6,907
7,339
7,434
7,628
7,679
7,783
8,052
Expenses
2,506
2,574
2,586
2,688
2,885
2,878
2,847
3,011
2,920
2,845
3,319
3,311
3,261
3,539
3,792
4,208
4,271
4,311
4,473
4,701
4,862
4,679
5,071
5,011
4,735
4,502
4,766
4,993
5,002
5,303
4,950
5,453
5,477
5,772
5,846
5,753
6,042
5,949
6,230
6,401
EBITDA
645
698
738
762
825
851
895
860
704
800
1,047
992
772
687
902
1,033
963
1,066
1,066
1,130
1,247
1,271
1,361
4,290
1,335
1,300
1,220
1,096
842
914
781
1,027
1,037
1,135
1,493
1,681
1,585
1,730
1,553
1,652
Operating Profit %
20 %
21 %
22 %
22 %
21 %
22 %
23 %
22 %
18 %
21 %
24 %
22 %
18 %
15 %
19 %
19 %
18 %
20 %
19 %
19 %
20 %
20 %
20 %
21 %
21 %
21 %
19 %
17 %
14 %
14 %
13 %
15 %
14 %
15 %
18 %
21 %
19 %
20 %
19 %
19 %
Depreciation
85
89
93
99
111
106
110
111
100
131
132
138
157
155
164
163
187
241
243
250
232
256
257
277
266
280
294
299
254
280
298
321
346
327
418
423
354
404
382
419
Interest
21
31
68
9
25
21
18
14
14
17
17
19
25
30
35
48
50
50
41
37
32
21
16
20
18
13
10
16
9
15
25
45
56
57
68
76
89
111
113
119
Profit Before Tax
557
634
631
717
761
786
830
796
649
709
979
902
651
571
787
917
816
863
864
938
1,078
1,084
1,193
4,005
1,061
1,018
968
794
594
679
523
680
730
812
1,076
1,262
1,230
1,324
1,208
1,200
Tax
153
162
178
173
206
201
224
218
117
191
198
307
122
116
175
205
231
228
224
233
229
301
386
1,058
260
248
271
190
18
159
113
189
224
242
324
323
323
406
391
354
Net Profit
403
472
453
545
555
585
606
579
532
518
781
595
529
456
611
712
585
636
640
705
849
783
807
2,948
801
770
697
604
576
520
410
491
506
570
752
940
907
918
817
846
EPS in ₹
13.84
16.18
7.77
9.32
9.49
9.99
10.41
9.88
9.10
8.85
13.33
10.16
9.02
7.78
10.44
12.15
9.99
10.85
10.92
12.04
14.50
13.32
13.78
50.31
13.67
13.14
11.89
10.32
9.84
8.88
6.99
8.38
8.64
9.74
12.83
16.04
15.51
15.69
14.00
14.56

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,397
9,374
10,532
11,024
14,493
Current Assets
8,299
10,294
9,206
12,178
15,332
16,413
19,824
18,123
21,460
23,772
Capital Work in Progress
420
848
1,458
1,583
1,669
1,986
3,062
3,747
5,390
3,869
Investments
20
123
246
312
360
555
591
997
543
372
Other Assets
8,770
10,769
9,712
12,686
15,951
16,991
20,828
18,645
22,934
26,338
Total Liabilities
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
Current Liabilities
6,136
7,840
6,606
8,666
12,021
11,385
10,665
8,156
11,494
12,199
Non Current Liabilities
1,596
790
270
753
541
718
1,260
1,192
1,544
3,022
Total Equity
5,182
7,290
9,374
11,682
13,892
16,825
21,929
24,574
26,852
29,851
Reserve & Surplus
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
Share Capital
29
59
59
59
59
59
59
59
59
59

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
Investing Activities
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
Operating Activities
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,017
2,387
2,435
Financing Activities
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
51.94 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.80 %
51.82 %
51.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
18.02 %
16.73 %
16.59 %
16.29 %
DIIs
10.99 %
12.72 %
13.82 %
15.11 %
15.83 %
15.58 %
16.23 %
14.89 %
15.08 %
15.73 %
17.94 %
20.23 %
23.28 %
24.77 %
25.13 %
25.20 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.71 %
8.54 %
9.60 %
8.99 %
8.37 %
8.80 %
8.65 %
9.42 %
8.54 %
7.01 %
6.15 %
5.64 %
5.52 %
5.47 %
5.33 %
5.52 %
Others
28.36 %
26.91 %
24.74 %
24.07 %
23.97 %
23.79 %
23.29 %
23.85 %
24.54 %
25.42 %
24.07 %
22.29 %
1.36 %
1.23 %
1.13 %
1.17 %
No of Share Holders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 2.5 2.5 3 4 9 7.5 4.5 0.00
Dividend Yield (%) 0.00 0.57 0.32 0.61 0.34 0.6 1.77 0.69 0.39 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Completion Of US FDA Inspection At Raleigh Plant North Carolina Owned By Aurolife Pharma LLC A Wholly Owned Step-Down Subsidiary Of The Company3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Curateq Biologics Received Marketing Authorization For Dyrupegâ„¢ A Pegylated Filgrastim Biosimilar9 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 31, 2025
Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 28, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Closure of Trading WindowMar 25, 2025
Allotment Of Compulsory Convertible Preference Shares To Dr. Satakarni Makkapati By Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company.Mar 21, 2025
Classification Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company - Reg.Mar 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Termination Of License Agreement With Hilleman Laboratories Singapore Pte Limited By Auro Vaccines Private LimitedMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 28, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Classification Of US FDA Inspection At One Of The Warehouses Of Aurobindo Pharma USA Inc. A 100% Subsidiary Of The Company.Feb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited A 100% Stepdown Subsidiary Of The CompanyFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Curateq Biologics Received Marketing Authorisation For Zefylti® A Filgrastim BiosimilarFeb 13, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Integrated Filing (Financial)Feb 07, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 06, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 06, 2025
Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31 2024Feb 06, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On February 6 2025Feb 06, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Press Release - Curateq Biologics S.R.O Receives Positive Opinion From CHMP / EMA For DyrupegJan 31, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2025
Unit 2 Of Apitoria Pharma Pvt. Ltd. Received EIR From US FDA With VAI ClassificationJan 28, 2025
Board Meeting Intimation for Intimation Of Board MeetingJan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Warning Letter Received From NSE With Regard To Corporate Announcements Submitted In Letter Head Of The Company Where-In PAN Of The Company Was MentionedDec 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 27, 2024

Technical Indicators

RSI(14)
Neutral
41.61
ATR(14)
Less Volatile
52.17
STOCH(9,6)
Neutral
29.68
STOCH RSI(14)
Oversold
6.90
MACD(12,26)
Bearish
-9.87
ADX(14)
Weak Trend
17.07
UO(9)
Bearish
46.03
ROC(12)
Downtrend And Accelerating
-10.51
WillR(14)
Neutral
-71.84

About Aurobindo Pharma

Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has 9 R&D facilities. APL has filed numerous Drug Master Files and Abbreviated New Drug Applications in various countries. The company has expanded through acquisitions and joint ventures in multiple countries, including the UK, Italy, and Portugal. APL has also entered the biosimilars and vaccines markets. The company serves over 150 countries and is among the top 5 manufacturers of semi-synthetic penicillins globally.
Chairperson NameM R Kumar